Recently, InhalPharma announced the completion of a nearly 100 million RMB Series B financing round. This round was led by the Beijing Medical Health Industry Investment Fund, with participation from investors including Sanze Ventures. The funds will focus on three key directions:

Advancing clinical breakthroughs for core pipelines, building a world-leading peptide inhalation delivery platform, and accelerating the international roll-outs of innovative products,

which will comprehensively solidify InhalPharma's full-chain competitive advantage in the field of dry powder inhalation drug delivery.

InhalPharma(hereinafter also "The Company") is a high-tech enterprise specializing in "pharmaceutical-device combination dry powder inhalation (DPI) drug delivery innovation." It integrates R&D, production, and sales, primarily focusing on developing dry powder inhalation formulations for respiratory and cardiovascular diseases. The Company has achieved an integrated closed-loop from laboratory technology to industrial production and commercial promotion. This successful financing round not only represents deep capital market recognition of its technical strength and strategic layout but also marks the Company's entry into a new three-vector development stage of "accelerated clinical progress + platform upgrade + global expansion".

01 Four Core Pipelines Advance in Tandem, Covering Clinically Essential Scenarios

● FD4001:A compound inhalation powder for asthma. It utilizes proprietary spheronization technology to optimize particle flowability.

Its lung deposition rate exceeds 50%, significantly out-performing traditional inhalation powders. It has entered a critical clinical stage and is expected to break the monopoly of international giants like AstraZeneca (AZ) and GSK in the high-end inhalation powder market.

● FD4014:A three-drug-combined inhalation powder for moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).

It deploys a proprietary dual-blister dry powder inhaler device and multi-component particle synergistic dispersion technology, solving challenges related to the coordinated delivery and stability of triple therapies. Its ease of administration and efficacy are benchmarked against the original innovator product, further expanding the Company's respiratory disease portfolio.

● F2008:A modified new drug targeting rare disease Idiopathic Pulmonary Fibrosis (IPF).

It re-purposes an existing drug via dry powder inhalation delivery for precise targeting of the lung-interstitium. This product will fill a gap in worldwide inhalation therapies for IPF. It will soon complete IND filings in both China and the US, with the potential to become Best-in-class.

● FD1016:An innovative inhalation drug for weight-loss.

It delivers GLP-1/GIP/GCG tri-agonist peptides via dry powder inhalation, entering the bloodstream through the lungs for long-acting fat reduction. This avoids the pain and wounds associated with subcutaneous injections. Compared to similar oral products, it offers a multi-fold increase in bioavailability, requires no refrigeration, meanwhile demonstrates superior stability to traditional injections, and also qualifies it to bacome First-in-class.

All four products are developed on the Company's full-chain dry powder inhalation drug delivery platform, achieving comprehensive autonomy and control from formulation design and device development to customizable production lines. The development cycle is shortened by approximately 3-5 years compared to the industry average, with significant cost advantages, fully covering clinically essential scenarios such as asthma, COPD, IPF, and weight-loss.

 

02 Multidimensional Upgrade of Technology Platforms, Fortifying Barriers to Entry in Substitution and Innovation

In core technology innovation, InhalPharma continues to break new grounds:

● DPI Technology Iteration & Update:

Proprietary development of innovative dry powder inhalers, including disc-blister type, single-dose type, and continuous-capsule type, addressing pin points of traditional devices such as improper use, operational inconvenience, with persistently high costs. Simultaneously, supporting equipment like customized ultra-fine powder micro-precision filling machines has been developed, successfully breaking the stranglehold of international giants. Costs are significantly lower than imported equipment, and the technology has already been industrialized.

● Building a Peptide Dry Powder Inhalation Delivery Platform:

This financing round will heavily invest in R&D for peptide drug inhalation delivery technology, tackling industry pin points like poor stability and low bioavailability of peptide drugs. The goal is to build a full-chain platform encompassing peptide molecular design, delivery system construction, inhaler matching, and industrial validation. This targets new emerging tracks like weight loss, anti-aging, and aging-related diseases, and addresses clinical needs for the benefit of patients.

● Expansion into Nasal Dry Powder Delivery Platform:

A new layout in nasal dry powder delivery technology, focusing on the treatment of Central Nervous System (CNS) diseases. By controlling drug particle size, optimizing formulations, and modifying nasal delivery devices, the aim is to achieve drug delivery to the brain via the olfactory region. Screening has begun for drugs targeting neurodegenerative and psychiatric disorders, filling a technological gap left by foreign companies in nasal-targeted CNS dry powder delivery.

Currently, the Company has formed product pipelines covering multiple fields including respiratory diseases, obesity, and metabolic diseases, striving to become a global leader in dry powder inhalation drug delivery innovation.

 

03 Accelerating International Roll-outs, Expanding Global Market Space

Leveraging this financing round, the Company will initiate international filings and market expansion for its innovative products. On the one hand, it will advance registration of clinical trials and promotion for its core pipelines in major markets like Europe and North America. On the other hand, it will build a global cooperation network, pushing its proprietary inhalation formulation technologies and products onto the global stage through models like technology licensing and joint development. This aims to break the market monopoly of international giants in high-end inhalation formulations and contribute to the global breakthrough of China's inhalation formulation industry.

 

04 Capital Empowerment, Ushering in a New Future for Inhalation Formulations

"Inhalation formulations represent a golden market combining high technical barriers with immense market potential. The global market exceeds 350 billion RMB, while the domestic market grows at an annual rate of 7.62%. However, high-end products have long been monopolized by imports, leaving a vast space for domestic substitution and internationalization," stated a representative from the lead investor. "InhalPharma's full-chain independent R&D capabilities, differentiated pipeline layout, and forward-looking technology platform planning precisely address industry pain points. We are optimistic about its leading role in China's domestic inhalation formulation sector and will continue to empower the Company's clinical advancement, platform construction, and global expansion."

Looking forward, the Company will adhere to a strategy of differentiation, internationalization, and continuous innovation, providing global patients with safer, more efficient, more accessible, and more cost-effective inhalation drug delivery solutions. This will help Chinese inhalation formulation industry take the leap from "Follower" to "Leader".

 

About Beijing Medical Health Industry Investment Fund

The Beijing Medical Health Industry Investment Fund is managed by Beijing Shunxi Private Equity Fund Management Co., Ltd. ("Shunxi Fund"). Shunxi Fund is a full-life-cycle investment platform under Beijing State-owned Assets Management Co., Ltd. (Beijing Guoguan), focusing on investments in strategic emerging industries. Since its establishment, Shunxi Fund has evolved from being positioned as a VC under Beijing Guoguan focused on "investing early, investing small, investing in technology, and investing in Beijing" to a full-lifecycle investment platform. By establishing strong cooperative relationships with numerous universities, research institutes, new R&D firms, municipal and district-level state-owned funds, market-oriented partner GPs, industry chain leaders, and government authorities, it continuously builds a multi-dimensional collaborative support system, accumulating unique advantages, diverse channels for high-quality project resources, and post-investment empowerment capabilities.

 

About Sanze Ventures

Founded in 2008, Sanze Ventures is a governing institute member of the Venture Capital Committee of the China Investment Association, a governing institute member of the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce, and a vice-chairman institute of both the Guangdong Venture Capital Promotion Association and the Hunan Equity Investment Association. The firm focuses on forward-looking investments in healthcare and technology innovation, covering various stages from startup to growth and development. It has built a complete ecosystem for investment, operation, and management, and has been recognized by awards such as Top 100 Best Venture Capital Institutions in China by ChinaVenture, Top 30 Best Investment Institutions in the Greater China Health Field, Top 50 Best VC Funds in China, Top 50 VC Funds with Best Returns by the China FOF Alliance, Best VC Institution by the Golden Eagle Award of China Venture Capital by Securities Times, and Top 100 China Venture Capital Institutions by Rongzhong. Adhering to the philosophy of "Three Creates Myriad of Things, Grace Nourishes All the Beings," Sanze Ventures is committed to providing personalized value-added investment services and safeguarding enterprise development.

 

 

Disclaimer: The intellectual property rights of the content published by Dongmai Wang are exclusively owned or held by Dongmai Wang and relevant right-holders. Unauthorized reproductions, excerpting, copying, or creating duplicates are prohibited. If corporate information and data are presented in the text, they are provided and confirmed by the interviewees to the analysts.